An observational study in Dry Eye Disease, sponsored by Scott & Christie and Associates, PC. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Scott & Christie and Associates, PC · Observational
Among 542 studies in Dry Eye Syndromes with a site in United States — 51 open to participants now, 61 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 542 studies in Dry Eye Syndromes with a site in United States, this one is the 27th largest by planned enrollment of the 63 observational ones that give a count, is one of 34 that started in 2026, is one of 63 observational ones, reaches primary completion later than 43 of the 60 other live ones, and was the 540th registered.
1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.
Browse Dry Eye Syndromes studies →51 of the 542 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Bausch & Lomb Incorporated · Sites in United States
Alcon Research · Sites in United States
Cleveland Eye Clinic · Sites in United States
Eye Research Associates, LLC · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
542 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 34 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 89 across 190 observational studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 472 interventional studies, 80 across the 63 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
329 of 542 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Scott & Christie and Associates, PC as lead sponsor.
Scott & Christie and Associates, PC has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
29 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-11 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Among the 542 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multi-center, prospective, open-label, single-arm effectiveness of acoltremon 0.003% in improving patient signs and symptoms with dry eye disease. Subjects will be assessed at baseline, and after 7, 14, and 28 days of treatment. Clinical evaluations will include administration of the Eye Dryness Score Visual Analog Scale (EDS-VAS), measurement of visual acuity at distance, corneal fluorescein staining, conjunctival lissamine green staining, and Pain Numerical Rating Scale assessment.
Patients aged 18 years and older with dry eye disease who present with corneal staining. Planned enrollment is 100 subjects at two sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acoltremon 0.003% (TRYPTYR)
1 drop per eye, twice daily (morning and evening approximately 12 hours apart), at consistent times.
Mean change from Baseline in Eye Dryness Score Visual Analog Scale (EDS-VAS).
Time frame: 28 days
Mean change from Baseline in corneal fluorescein staining.
Based in NEI grading scale. Five quadrants are graded (0-3) giving a total score (by summation) of 0-15 per eye. A higher score is a worse outcome.
Time frame: 28 days
Mean change from Baseline in conjunctival lissamine green staining.
Based in NEI grading scale. Six quadrants are graded (0-3) giving a total score (by summation) of 0-18 per eye. A higher score is a worse outcome.
Time frame: 28 days
Mean change from Baseline in corneal fluorescein staining.
Based in NEI grading scale. Five quadrants are graded (0-3) giving a total score (by summation) of 0-15 per eye. A higher score is a worse outcome.
Time frame: 7 days
Mean change from Baseline in corneal fluorescein staining.
Based in NEI grading scale. Five quadrants are graded (0-3) giving a total score (by summation) of 0-15 per eye. A higher score is a worse outcome.
Time frame: 14 days
Mean change from Baseline in conjunctival lissamine green staining.
Based in NEI grading scale. Six quadrants are graded (0-3) giving a total score (by summation) of 0-18 per eye. A higher score is a worse outcome.
Time frame: 7 days
Mean change from Baseline in conjunctival lissamine green staining.
Based in NEI grading scale. Six quadrants are graded (0-3) giving a total score (by summation) of 0-18 per eye. A higher score is a worse outcome.
Time frame: 14 days
Proportion of subjects who report at least one occurrence of ≥ 1-unit reduction compared to baseline for two consecutive recordings on the Pain Numerical Rating Scale (NRS) Assessment for instillation site sensation.
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 53 non-industry observational studies under Dry Eye Syndromes, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 8 months is below that.
Counting every sponsor, half of 69 studies reached it within 12 months; a quarter within 5 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.